<p>Internal radiation therapy is an irreplaceable modality for local tumor treatment, offering high-effective radiotherapy while sparing surrounding healthy tissues. However, current clinical non-biodegradable radionuclide implants suffer from permanent retention risks and limited efficacy against distal tumors due to inadequate immune activation. Herein, we engineered a biodegradable radionuclide-labeled oxygen-self-supplying calcium reservoir (<sup>131</sup>I@CaO<sub>2</sub>), fabricated through biomimetic mineralization followed by chloramine-T mediated <sup>131</sup>I-radiolabeling, for high-efficiency internal-radioimmunotherapy. <sup>131</sup>I@CaO<sub>2</sub> effectively enhances the internalization of <sup>131</sup>I to improve internal-radiotherapy and exhibits pH-responsive biodegradability, remaining stable under physiological condition while progressively degrading in tumor microenvironment to release H<sub>2</sub>O<sub>2</sub>, O<sub>2</sub> and Ca<sup>2+</sup>. These bioactivators synergistically enhance <sup>131</sup>I-induced internal-radioimmunotherapy through both radiosensitization and immune activation: H<sub>2</sub>O<sub>2</sub> and O<sub>2</sub> boost <sup>131</sup>I-induced ROS generation while Ca<sup>2+</sup> disrupted mitochondrial respiration to reduce oxygen consumption and ATP production (suppressing Ca<sup>2+</sup> pump activity), creating a positive feedback loop of oxygen supply and ion overload, thereby achieving radiosensitization; Concurrently, O<sub>2</sub> alleviates tumor hypoxia to downregulate PD-L1 expression and Ca<sup>2+</sup> overload activates dual pyroptosis pathways, establishing a robust immunogenic microenvironment. As a result, <sup>131</sup>I@CaO<sub>2</sub> effectively eliminates both primary and distant tumors by activating immune cells. This study simultaneously resolves the long-term retention risks of non-biodegradable radionuclide and the dichotomy between local radiotherapy and comprehensive immune modulation.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Radionuclide-labeled oxygen-self-supplying calcium reservoir for high-efficiency radioimmunotherapy via synergistic pyroptosis activation and PD-L1 downregulation

  • Lin Liu,
  • Kaiyan Huang,
  • Hanjing Guo,
  • Linping He,
  • Xin Wang,
  • Chao Wang,
  • Jianqing Lin,
  • Naihan Huang,
  • Weibing Miao

摘要

Internal radiation therapy is an irreplaceable modality for local tumor treatment, offering high-effective radiotherapy while sparing surrounding healthy tissues. However, current clinical non-biodegradable radionuclide implants suffer from permanent retention risks and limited efficacy against distal tumors due to inadequate immune activation. Herein, we engineered a biodegradable radionuclide-labeled oxygen-self-supplying calcium reservoir (131I@CaO2), fabricated through biomimetic mineralization followed by chloramine-T mediated 131I-radiolabeling, for high-efficiency internal-radioimmunotherapy. 131I@CaO2 effectively enhances the internalization of 131I to improve internal-radiotherapy and exhibits pH-responsive biodegradability, remaining stable under physiological condition while progressively degrading in tumor microenvironment to release H2O2, O2 and Ca2+. These bioactivators synergistically enhance 131I-induced internal-radioimmunotherapy through both radiosensitization and immune activation: H2O2 and O2 boost 131I-induced ROS generation while Ca2+ disrupted mitochondrial respiration to reduce oxygen consumption and ATP production (suppressing Ca2+ pump activity), creating a positive feedback loop of oxygen supply and ion overload, thereby achieving radiosensitization; Concurrently, O2 alleviates tumor hypoxia to downregulate PD-L1 expression and Ca2+ overload activates dual pyroptosis pathways, establishing a robust immunogenic microenvironment. As a result, 131I@CaO2 effectively eliminates both primary and distant tumors by activating immune cells. This study simultaneously resolves the long-term retention risks of non-biodegradable radionuclide and the dichotomy between local radiotherapy and comprehensive immune modulation.